Study drug CM93 for EGFR-mutated recurrent glioblastoma
Part of Cancer clinical trials.
This Phase 1 trial studies CM93 to treat adults with recurrent (coming back) glioblastoma that has an EGFR change in the tumor. It mainly aims to see how safe CM93 is and what dose might work best, while also gathering lab information from your tumor tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent or progressing WHO grade 4 glioblastoma (or a related high-grade brain tumor with glioblastoma-like features) that is IDH “wild type” (not IDH-mutated).
- Your tumor tissue from prior surgery must show an EGFR mutation or EGFR “extra copies” (amplification).
- You must have already had standard radiation for your first treatment, and your tumor must be confirmed growing on MRI with measurable disease.
- You need usable tumor samples from past surgery (either 1 tumor tissue block or 20 slides) so the team can test the EGFR again and do extra sequencing.
- You must be able to recover from prior treatment effects (symptoms at grade 0–1) and be at least 18 years old.
- Your blood counts and organ function must meet lab thresholds, and your heart pumping strength must be strong enough (left ventricular ejection fraction at least 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.